Exagen Agrees to Pay Over $650K to Resolve Kickback Allegations
By Denny Jacob
Exagen agreed to pay $650,143 to resolve allegations it paid specimen processing fees to referring physicians to induce their use of the company's laboratory tests.
The commercial-stage diagnostics company agreed to factual admissions that it paid certain referring physicians to complete blood draws for patients in connection to specimen processing agreements that Exagen entered into with those physicians, according to the Department of Justice.
Exagen billed federal healthcare programs, including Medicare, for tests it performed after receiving orders from the physicians, according to the settlement. The company did so even after becoming aware of a fraud alert in June from the Department of Health & Human Services' Office of the Inspector General.
DOJ said the settlement stems from allegations brought in a lawsuit filed by a whistleblower, who will receive 16% of the recovered settlement.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
October 17, 2023 14:35 ET (18:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom